Delisting riskPopularity #3,847
Context Therapeutics (CNTX)
Develops CD3-directed bispecific antibodies for solid tumors.
$0.3855
vs last close−0.00 (−0.93%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 68.61% | 63.04M shares | |
|---|---|---|---|
| 81 holders · as of Jun 30, 2026 | |||
| Insiders | 1.23% | 1.13M shares | |
| 3 holders · as of Jun 10, 2025 | |||
| Other | 30.16% | 27.71M shares | |
| remainder | |||
91.88M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
81 holders · 63.04M shares · 38 new positions · 57 increased · 12 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 7.42M | 8.08% | 0 | Aug 14, 2026 |
| Nextech Invest, Ltd. | 7.42M | 8.08% | 0 | Aug 14, 2026 |
| Soleus Capital Management, L.P. | 7.06M | 7.69% | +100.0K | Aug 11, 2026 |
| BlackRock, Inc. | 6.17M | 6.71% | +5.32M | Aug 7, 2026 |
| Avidity Partners Management LP | 5.00M | 5.44% | 0 | Aug 14, 2026 |
| Franklin Resources Inc | 3.80M | 4.14% | 0 | Aug 13, 2026 |
| Vanguard Capital Management LLC | 3.43M | 3.74% | +99 | Aug 13, 2026 |
| Octagon Capital Advisors LP | 3.05M | 3.32% | −2.20M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| MPM BioImpact LLC | 11.60% | 10.68M | 13G | Feb 17, 2026 |
| Avidity Partners Management LP | 8.70% | 8.30M | 13G | May 12, 2026 |
| Deep Track Capital, LP | 8.27% | 7.42M | 13G | May 15, 2025 |
| Soleus Capital Master Fund, L.P. | 7.60% | 6.96M | 13G | May 8, 2026 |
| BlackRock, Inc. | 6.70% | 6.17M | 13G | Jul 27, 2026 |
| Octagon Capital Advisors LP | 5.70% | 5.25M | 13G | May 14, 2026 |
| Blue Owl Capital Holdings LP | 5.54% | 5.09M | 13G | May 14, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.